Dr. Eric Olson to Provide CRISPR/Cas9 and Gene Therapy Update During November 16 Webinar
We are delighted that Exonics Therapeutics has closed a $40 million Series A financing with The Column Group (TCG) to advance its lead SingleCut CRISPR gene editing program in Duchenne muscular dystrophy and potentially other neuromuscular diseases. CureDuchenne Ventures helped found Exonics and provided the seed financing which has enabled the company to establish a strong scientific and corporate foundation. We are proud that CureDuchenne has been able to advance the work of Dr. Eric Olson from the University of Texas Southwestern Medical Center.
“We are grateful for CureDuchenne Ventures for their support and partnership with Exonics from its inception,” said Dr. Olson. “CureDuchenne’s seed financing helped us accelerate our gene editing program. It is remarkable, in just nine months, to have a leading healthcare venture capital firm validate the potential for our research and it is a testament to CureDuchenne’s successful track record of supporting next generation research.”
Preclinical data support the development of a safe and efficacious one-time gene editing treatment leveraging SingleCut CRISPR to potentially provide lifelong benefit for patients with Duchenne. Dr. Olson’s gene editing therapy has the potential to identify and repair exon mutations that prevent the production of dystrophin, the key protein missing in children with Duchenne that helps establish and protect muscle fibers.
CureDuchenne will host a CRISPR/Cas9 and Gene Therapy for Duchenne Webinar with Dr. Eric Olson on Thursday, November 16 at 3 p.m. ET/noon PT. The call-in number is: 888-378-4398 Passcode 393023. Click here to register for the webinar and learn more about Dr. Olson’s research.
Thanks to donors, sponsors and others who contributed to CureDuchenne’s support of Dr. Olson’s CRISPR gene editing research. We are grateful for your support in helping to save the lives of children and young adults with Duchenne. We are hopeful that CRISPR gene editing ultimately offers a significant impactful treatment for those affected by Duchenne.
This is still early science and there is still a lot of work to do to advance multiple exon programs. We need your continued support to help fund and accelerate promising CRISPR research to bring a cure for as many Duchenne patients as possible. We need to continue to address and treat all aspects of the disease.
Accelerating drug development and improving Duchenne care, that’s what CureDuchenne is all about.